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Background: Alpha1-antitrypsin (AAT) deficiency is under-recognized, probably
because many individuals affected show no clinical impairment. The targeted
detection is a tool to increase its recognition.
Methods: We prospectively submitted to AAT serum levels determination, pheno-
typing and, if doubtful, genotyping: (i) patients with the early onset of emphysema,
emphysema in absence of recognized risk or pneumothorax (path P), antineutrophil
cytoplasm antibodies (ANCA) positive vasculitis (path V), cervical artery dissection
(path A), Periodic acid-Schiff (PAS) positive bodies in the liver cell or unexplained
abnormal transaminase level (Path L) [index cases: IC] and (ii) subjects with low-
serum alpha1-globulin (path e) and close relatives of patients with AAT deficiency
(path r) [non index cases: NIC]. We determined and compared gender, age, AAT
serum levels values, the ratio between AAT deficiency subjects identified and all
subjects examined (identified/examined). Receiver operating characteristic (ROC)
curve was plotted to find the best threshold for AAT serum levels.
Results: Two hundred and eighty-five individuals were examined and 211 with AAT
deficiency identified: 66 were IC and 145 NIC. The ratio identified/examined
resulted 0.74. A serum level of 120mg/dL was able to identify AAT deficiency with a
specificity of 73% and a sensitivity of 97%. IC showed male prevalence (P ¼ 0:005),
more advanced age (P ¼ 0:02), lower AAT serum levels (P ¼ 0:008).Elsevier Ltd. All rights reserved.
Ente Universitario Lombardia Orientale, Brescia, Italy).
3995237; fax +39 0303770451.
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L. Corda et al.464Conclusions: Our protocol is effective to detect AAT deficiency in a selected
population. About 120mg/dL (nephelometric method) is a reliable AAT serum level
cut-off for selecting subjects/patients to submit to phenotype or genotype; as
compared to NIC, IC are older, mostly male and with lower AAT serum levels.
& 2005 Elsevier Ltd. All rights reserved.Cervical artery dissection
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Figure 1 The flow chart adopted to identify patients (IC)
or subjects (NIC) affected by AAT deficiency. (PAS:
periodic acid-Schiff; ALT: alanine transferase; AST:
aspartate transaminase; P ¼ pulmonary diseases; A ¼
cervical artery dissection; L ¼ liver disease; V ¼ vasculitis;
e ¼ low alpha1-band at electrophoresis; r ¼ relative
of an IC).Introduction
Alpha1-antitrypsin (AAT) is a glycoprotein produced
mainly by hepatocytes. Its essential action is to
inhibit neutrophil elastase. It is coded by a
polymorphic gene located on chromosome
14q32.1, where at least 75 alleles have been
identified. These alleles may be classified as either
normal (M) or deficient (Z, S, null, Mlike, Mmalton,
I.). The two parental alleles are codominant and
both contribute to AAT serum concentration. With
the nephelometric method of dosage the normal
range of AAT serum levels is reported as being
between 200/220 and 83/120mg/dL.1,2 AAT defi-
ciency is an inherited disorder characterized by a
low AAT serum level.3 Since AAT deficiency was
recognized, there have been advances in our
knowledge of this disorder. Genetics, molecular
basis and some clinical manifestations are now
better understood and described, while augmenta-
tion therapy for patients affected by pulmonary
emphysema and COPD is now available. There is a
clear relationship between the ZZ and nullnull
phenotype and the risk of early emphysema, liver
disease or, more rarely, skin disease. The SZ
phenotype is not recognized as a risk factor, even
if among SZ smokers the risk of airflow obstruction
seems to be similar to that of ZZ individuals.4
However, in spite of recent extensive efforts to
identify cases with AAT deficiency, the disorder is
largely under-recognized, most probably due to the
fact that many individuals with AAT deficiency do
not have significant clinical impairment.5
In 1996, a program for detecting AAT deficiency
in Italy was started in order to improve knowledge
of this condition and to create a registry of AAT
deficient subjects.6
The main purpose of the present study was to
develop and assess a targeted detection protocol
conceived to identify as many AAT deficient
subjects/patients as possible. The secondary aims
were to identify a cut-off value for AAT serum level
below which it might be useful to ascertain the
phenotype or the genotype and to study the
difference between index cases (IC) (symptomatic
patients detected because of a related disease) and
non-index cases (NIC) (asymptomatic subjects
detected as relatives of IC or because of low alpha1
globulin level found with electrophoresis).Methods
After approval by the local Ethical Committee, in
the period from January 1996 to December 2004,
we prospectively searched for subjects or patients
affected by AAT deficiency following the protocol
shown in Fig. 1. Accordingly, we submitted hospital
patients with high suspicion of AAT deficiency to
AAT serum level determinations (nephelometric
method), during stable clinical conditions and with
the certainty that they were not taking drugs like
progesterone or estrogens. These patients were
affected by: (1) the early onset of emphysema (at
the age of 45 or less), emphysema in the absence of
recognized risk factors (i.e. smoking, occupational
dust exposure) or spontaneous pneumothorax (we
named this diagnostic approach path ‘‘P’’); (2)
cervical artery dissection (CAD) (path ‘‘A’’); (3) PAS
(periodic acid-Schiff) positive bodies in the liver
cell cytoplasm, in specimens from liver biopsy,
suggesting AAT pathological accumulation (path
‘‘L’’); (4) an unexplained and isolated abnormal
level of transaminases (path ‘‘L’’); (5) ANCA
(antineutrophil cytoplasm antibodies) positive vas-
culitis (path ‘‘V’’); (6) low alpha1 globulin level at
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Targeted detection of alpha1-antitrypsin deficiency 465electrophoresis according to our laboratory refer-
ence values (o200mg/dL) (path ‘‘e’’). AAT pheno-
typing in dried blood specimens absorbed on special
paper was performed7 to prove AAT deficiency. If
the phenotyping of the pathological alleles was
uncertain, genotyping was performed with a poly-
merase chain reaction (PCR) method and the direct
sequencing of AAT exons II–V using amplification
primers and sequencing primers.8 The patients
examined by paths P, A, L and V were considered
IC, while the subjects examined by path ‘‘e’’ were
considered NIC. In addition, we considered NIC
(path ‘‘r’’) the parents, offspring or siblings of a
patient or subject examined in an out-hospital
population (with regard to this, we advise testing of
all close relatives of any subjects identified, both
homozygous and heterozygous). All IC patients and
NIC (path e) subjects were referred to us from
different divisions of our hospital (Internal Medi-
cine, Nephrology, Neurology, Pathology). The NIC
subjects (path ‘‘r’’) were approached by their IC
relative and they referred to us with the logistic
support of the Italian Association of Patients
affected by AAT deficiency.
Based on the phenotype or genotype we defined,
the patients or subjects affected by AAT deficiency
as: (1) homozygous deficient if both alleles were
pathological and identical (i.e. ZZ); (2) double
heterozygous deficient if the alleles were patholo-
gical but of a different kind (i.e. SZ, ZMmalton); (3)
heterozygous deficient if only one allele was
pathological (i.e. MZ, MS, MMmalton). We divided
all the subjects studied, both IC and NIC, into two
groups, those with AAT deficiency and those with-
out. We evaluated, in all subjects with identified
AAT deficiency and again in both groups, the
distribution of the paths of identification and the
ratio between the subjects with identified AAT
deficiency and all the subjects examined (identi-
fied/examined). Following which, after grouping
the patients or subjects identified as deficient
according to their pathological phenotype or
genotype, we determined the distribution of
gender, the male/female ratio, the values of AAT
serum levels and their age at the time of diagnosis.
Since a low limit of AAT serum level would be
warranted in order to identify as many subjects as
possible for phenotyping or genotyping, we tried to
detect the best cut-off value for AAT serum levels
from the values of all the subjects studied.Statistic analysis
Each value is shown as mean7SD. The male/female
ratios of different groups were compared by w2test. The variables of interest were compared in
each group using the unpaired Student’s t-test. A P-
value of less than 0.05 was considered significant.
We plotted the receiver operating characteristic
(ROC) curve to find the best threshold for AATserum
levels, for which we calculated the specificity, the
sensitivity, the positive and negative predictive
values and the likelihood of a positive ratio.Results
Over 9 years 285 individuals were examined, and
211 (66 IC, 145 NIC) patients or subjects affected by
AAT deficiency were identified. The remaining 74
were identified as MM (that are not affected by AAT
deficiency).
Out of the 211 subjects with AAT deficiency, 108
(51%) were identified by path r, 37 (18%) by path e,
33 (15%) by path P, 29 (14%) by path L, three (1.5%)
by path A, one patient (0.5%) by path V. The ratio
between the subjects with identified AAT defi-
ciency and all other subjects examined (identified/
examined) was 0.74, while for each path this ratio
was 0.85 for path P, 1 for path A, 0.91 for path L, 1
for path V, 0.93 for path e, 0.64 for path r,
respectively (Table 1).
Seventy-four subjects had a MM phenotype; six of
them were affected by pulmonary disease, three by
liver disease while 62 were examined following
path r and three path e (Table 1).
A genotype was needed to define the rare AAT-
deficient variant after an uncertain phenotype in 14
subjects (one ZI, one ZMmalton, one M3Z, four M2Z,
two M2S, five MMmalton).
Forty-five out of 211 subjects (21%) had homo-
zygous or double heterozygous AAT deficiency. Out
of these 26 (12% of all cases) had a homozygous ZZ
phenotype; 15 (7%) were IC (12 were affected by
pulmonary emphysema, two by liver disease and
one by CAD) and 11 (5%) were NIC. Nineteen (9%)
were double heterozygous, 17 of which (8%) SZ;
four (2%) were IC (three affected by pulmonary
emphysema and one by liver disease) and 13 (6%)
NIC. Two male patients needed genotype confirma-
tion: one was ZI, the other ZMmalton. Both were
affected by pulmonary emphysema and thus con-
sidered as IC.
One hundred and sixty-six subjects/patients out
of 211 (79%) had heterozygous AAT deficiency. Out
of these 131 (62%) were MZ; 31 (15%) were IC (20
with liver disease, 10 with pulmonary emphysema,
one with Wegener granulomatosis) and 100 (47%)
NIC. Twenty-nine (14%) had MS phenotype; nine of
them (3%) were IC (three with liver disease, two
ARTICLE IN PRESS
Table 1 Distribution of each identification path according to phenotype or genotype and ratio identified/
examined for all subjects studied and for each path (P ¼ pulmonary diseases, A ¼ cervical artery dissection,
L ¼ liver disease, V ¼ vasculitis, e ¼ low alpha1-band at electrophoresis, r ¼ relative of an Index Case,
AATD ¼ Alpha1-antitrypsin deficiency subjects).
Subjects/patients Path of identification
All paths P A L V e r
ZZ 26 12 1 2 0 3 8
SZ 17 3 0 1 0 6 7
ZMmalton 1 1 0 0 0 0 0
ZI 1 1 0 0 0 0 0
MZ 131 10 0 20 1 20 80
MS 29 4 2 3 0 7 13
MMmalton 6 2 0 3 0 1 0
Total AATD identified 211 33 3 29 1 37 108
MM 74 6 0 3 0 3 62
Total examined 285 39 3 32 1 40 170
Identified/examined 0.74 0.85 1 0.91 1 0.93 0.64
L. Corda et al.466with spontaneous pneumothorax, two with CAD,
two with pulmonary emphysema) and 20 (9%) NIC.
Six out of 211 (3%) were MMmalton; all but one were
IC (three with liver disease and two with pulmonary
emphysema).
A different gender distribution with a male
prevalence was found between IC and NIC in
the groups ZZ (P ¼ 0:008), SZ (P ¼ 0:02), MS (P ¼
0:0003) and in all subjects with AAT deficiency
(P ¼ 0:005). The IC were older in the group ZZ
(P ¼ 0:008), and in all subjects with AAT deficiency
(P ¼ 0:02) as compared to NIC. A significant
difference of AAT plasma level between IC and
NIC was found in all subjects with AAT deficiency
(P ¼ 0:008) and in MS (P ¼ 0:03) and ZZ (P ¼ 0:04)
groups (Table 2).
The ROC curve identified a level of 120mg/dL as
the best cut-off value for selecting patients
suspected of AAT deficiency to submit to phenotype
or genotype testing. The sensitivity and specificity
of this cut-off value was 97% and 73%, respectively
(Fig. 2). Its positive predictive value was 92% and
its negative predictive value was 90%, with a
positive likelihood ratio of 3.6.Discussion
The following information emerged from this study:
(i) the current protocol is effective at detecting
AAT deficient subjects/patients; (ii) the AAT serum
level of 120mg/dl has good sensitivity and speci-
ficity and represents a valuable cut-off value to
search for AAT deficiency; (iii) IC are older, mostlymale, with a lower AATserum level, as compared to
NIC.
Although the knowledge of the genetics under-
lying this disease, and the technology for screening
and detection are rapidly advancing, the most
appropriate screening and detection methodologies
in terms of a target population and yield of positive
tests have not yet been well defined.9 Clearly, the
best way to identify as many subjects affected by
AAT deficiency as possible would be a widespread
screening of all patients with airflow obstruction,
as recommended by WHO,10 but from a cost-
effective point of view a targeted screening would
appear to be more appropriate. For this purpose,
we feel our protocol represents an effective
procedure for discovering subjects or patients with
AAT deficiency in a selected population. In fact, the
ratio between subjects identified and subjects
examined (identified/examined), considered by us
as a reliable index of effectiveness, ranges from 1
(paths A and V) to 0.64 (path r) with a value of 0.74
for all cases (Table 1). This algorithm provides some
suggestions about which subjects should be exam-
ined and how, along with the inclusion criteria for
targeted detection. The ATS/ERS Statement2 sug-
gests a prompt concern about AAT deficiency for: (i)
the early onset of emphysema, (ii) basilar emphy-
sema in the absence of a recognized risk, (iii)
individuals with unexplained liver disease, (iv)
adults with necrotizing panniculitis, (v) ANCA
positive vasculitis, (vi) a family history of emphy-
sema, bronchiectasis, liver disease or panniculitis,
(vii) bronchiectasis without evident aetiology, (viii)
siblings of an individual with AAT deficiency. In line
with the Statement, our protocol also provides two
ARTICLE IN PRESS
Table 2 Characteristics (number, gender, ratio male/female [m/f], Alpha1-antitrypsin [AAT] serum level and
age at the time of diagnosis) of different groups of subjects studied, according to their AAT phenotype or
genotype (pts ¼ patients, sbs ¼ subjects. N.S. ¼ not significant. AATD ¼ Alpha1-antitrypsin deficiency).
Number
(pts/sbs)
M F Ratio
(m/f)
P AAT
(mg/dL)
P Age P
Examined 285 145 140 1.1 92736 46717
Index 75 49 26 1.9 77734 49715
0.0001 0.0002 N.S.
Non-index 210 96 114 0.8 98735 46717
With AATD 211 110 101 1.1 78728 46717
Index 66 40 26 1.5 70730 49715
0.005 0.008 0.02
Non-index 145 70 75 0.9 81727 44717
Homozygous
ZZ 26 11 15 0.7 2477 46715
Index 15 9 6 1.5 2678 53714
0.008 0.04 0.008
Non-index 11 2 9 0.3 20714 35711
Double heterozygous
SZ 17 8 9 0.9 58710 48719
Index 4 3 1 3 6171 49721
0.02 N.S. N.S.
Non-index 13 5 8 0.6 57710 48711
ZMmalton (Index) 1 1 0 — 20 32
ZI (Index) 1 1 0 — 58 55
Heterozygous
MZ 131 68 63 1.1 85716 45717
Index 31 17 14 1.3 87717 48717
N.S. N.S. N.S.
Non-index 100 51 49 1.0 85717 45717
MS 29 17 12 1.4 106720 49714
Index 9 7 2 3.5 94714 49717
0.0003 0.03 N.S.
Non-index 20 11 9 1.2 111721 49715
MMmalton 6 3 3 1 77714 57716 N.S.
Index 5 2 3 0.7 75715 53714
Non-index 1 1 0 — 81 79
Without AATD (MM) 74 35 39 0.9 133721 47717
Index 9 9 0 — 129719 43715
N.S. N.S.
Non-index 65 26 39 0.7 134722 48718
Targeted detection of alpha1-antitrypsin deficiency 467categories: the diagnostic category (which refers to
individuals with signs and/or symptoms consistent
with AAT deficiency) and the predispositional
category (which refers to asymptomatic individuals
with a high risk of AAT deficiency). The present
algorithm differs little from this Statement, the
differences being the inclusion of patients with
cervical arterial dissection or with spontaneous
pneumothorax along with a more important role
attributed to plasma protein electrophoresis.
For these reasons, some aspects of the identifi-
cation paths we followed deserve comment.In only two MS patients with spontaneous
pneumothorax, were subpleural blebs detected by
high-resolution computed tomography. Our findings
support the studies showing that spontaneous
pneumothorax is not associated with a higher
prevalence of AAT deficiency and therefore should
not be searched routinely for in these patients.11
We found 29 patients affected by liver disease
(two ZZ, one SZ, 20 MZ, three MS, three Mmalton). In
the presence of the common deficient variant (Z)
and rare variants (i.e. Mmalton, Siiyama and others)
AAT accumulates within the liver cells, inducing
ARTICLE IN PRESS
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L. Corda et al.468hepatocellular damage which in most individuals is
a pathological finding that remains largely sub-
clinical. Patients with heterozygous AAT deficiency
and one Z allele also bear an increased risk of
various chronic liver diseases including cirrhosis.12
Only one MZ patient was identified by path ‘‘V’’. A
high incidence of the Z variant, either in the
homozygous (ZZ) or in the heterozygous (MZ) state,
had previously been found in patients with systemic
vasculitis.13–15 AAT reacts specifically against pro-
teinase-3 (PR3), which in turn represents the target
antigen for anti-PR3 antibodies. Hence, the Z gene
carrier state could be either an aetiological risk
factor for the initiation of systemic vasculitis or a
determinant of the disease course once the
pathological process has started. In accordance
with the small number of patients identified by
path ‘‘V’’, the latter possibility is the most likely.16
We identified three patients affected by CAD
(one ZZ, two MS). By disturbing the balance
between elastase and antielastase AAT deficiency
might favour the degradation of the extracellular
matrix, contributing to the arterial damage pro-
cess. AAT deficiency has been suggested as a
potential risk factor for aortic aneurysm17 and for
CAD18; in addition, the distensibility of the aorta is
increased in men with AAT deficiency.19 AAT has
been found attached to endothelial cells in a
polymerized form and the loss of antiprotease
serpins could predispose the arteries to vascular
injury.20 The magnitude of these potential AAT-
dependent effects might be higher when transient
triggering mechanisms predisposing to CAD, such as
recent infections are operant21 and in vessels such
as carotid arteries, in which the elastic component
is greater.22It is useful to underline the need to perform AAT
dosage in stable clinical conditions, as carried out
by our team, because no single MZ individual can be
detected without phenotype or genotype during
the acute-phase reaction.23
With our protocol, a number of rare AAT
mutations were detected by DNA analysis per-
formed with mutagenic PCR and gene sequencing,
since the isoelectric focusing method cannot be
conclusive with regard to the rare variants. Indeed,
variants such as Mmalton are of clinical relevance
because five out of six subjects identified with this
allele, either double heterozygous or heterozygous,
were IC.
We found a relevant number (45 patients) of
heterozygous IC with either pulmonary or other
diseases. In a longitudinal study, it was argued that
28 MZ subjects were at higher risk of developing
pulmonary emphysema than 28 matched normal
subjects without AAT deficiency.24 Furthermore,
heterozygotes with phenotype MZ have an in-
creased risk of hospital admission because of COPD
if they are siblings or close relatives of ZZ IC.25
Therefore, both homozygous and heterozygous is a
condition that must be ascertained in every subject
with a high suspicion of AAT deficiency. In addition,
a recent meta-analysis suggested that the risk of
COPD in MZ heterozygotes is uncertain,26 thus an
effort to identify a large number of heterozygotes
might be useful to definitely ascertain the presence
and magnitude of the risk of COPD or other diseases
in these individuals. It could be argued that the
term ‘‘AAT deficiency’’ is debatable when addres-
sing patients with MS or even MZ phenotypes/
genotypes. In these patients, the AAT serum levels
are above the threshold value associated, for
instance, with the development of pulmonary
emphysema, but the real risk of these subjects is
not currently known. For this reason the reference
values should have a lower limit of 120mg/dl
instead of 80mg/dL. Out of the subjects or patients
we identified, 112 of them had an AAT serum level
ranging between 80 and 120mg/dL: by considering
80 as the low normal limit, we would have
misdiagnosed them.
The ROC curve revealed an optimal sensitivity
and good specificity for 120mg/dL, with a positive
and negative predictive value adequate for identi-
fying subjects to test with phenotyping or genotyp-
ing. Accordingly, phenotype/genotype should only
be performed if AAT serum levels are o120mg/dL.
This cut-off value cannot be generalized because
there are differences in reference values according
to each technique adopted (rocket immunoelec-
trophoresis and radial immunodiffusion besides
nephelometry). A cut-off value with a widely
ARTICLE IN PRESS
Targeted detection of alpha1-antitrypsin deficiency 469accepted quantitative technique might represent a
useful approach for the targeted detection of AAT
deficiency in the future. Finally, a targeted detec-
tion program would be preferable based on a
relatively high AAT plasma level of 120mg/dL in
order to identify also heterozygotes.
Although the main purpose of this study was to
develop and assess a targeted detection protocol,
from the epidemiological point of view it could be
considered an incidence study; consequently, the
subgroup analyses and subsequent conclusions need
to be interpreted with some caution. The IC group
was mostly male and older than the NIC group. If
this difference is related to lifestyle or genetic
factors it remains to be elucidated. Moreover, IC, as
a whole group, showed a significantly lower AAT
serum level. It is difficult to explain this difference
but, to a large extent, it is due to the MS and ZZ
subgroups (Table 1). It was observed that in
subjects with severe AAT deficiency survival was
lesser in patients identified by pulmonary impair-
ment (IC)27 than in subjects identified by family
studies (NIC), regardless of whether they smoked or
not; in addition, survival in the NIC non-smoker was
similar to that of the general population.28 Thus,
the likelihood of severe AAT deficiency-related
respiratory disease is probably less than previously
believed and, although smoking is a major risk
factor, the development of pulmonary emphysema
in subjects with AAT deficiency might be multi-
factorial, due either to unknown genetic factors,
environmental influence or both.
In conclusion, the results obtained show the
current protocol as effective for finding subjects or
patients with AAT deficiency in a selected popula-
tion. In addition, the serum level cut-off we
identified, might be used in a very large non-
selected population, avoiding excessive phenotyp-
ing or genotyping. IC were older, mostly male and
characterized by lower AAT serum levels as com-
pared to NIC; IC could be heterozygous and
affected also by diseases other than lung and liver
illnesses, although such disorders were the most
common. In our experience, 120mg/dL (nephelo-
metric method) was shown to be a reliable cut-off
value of AAT serum level for selecting subjects/
patients to submit to phenotyping or genotyping.Acknowledgements
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